LOS ANGELES, Oct. 23, 2024 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointme ...

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities who purchased or otherwise acquired Elanco Animal Health Incorporated (NYSE: ELAN) securities between November 7, 2023 and June 26, 2024. Elanco is an animal health company that develops, manufactures, and markets products for pets and farm animals. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. T ...

Core Viewpoint - A class action lawsuit has been filed against Elanco Animal Health Incorporated for allegedly misleading investors regarding the safety and approval timelines of its drugs Zenrelia and Credelio Quattro [1][3]. Group 1: Lawsuit Details - The lawsuit was filed in the U.S. District Court for the District of Maryland on behalf of investors who acquired Elanco securities between November 7, 2023, and June 26, 2024 [1]. - Investors have until December 6, 2024, to apply to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Product Approval Timeline - Elanco initially set a timeline for U.S. approval of Zenrelia and Credelio Quattro for the first half of 2024, but later delayed the approval to the third quarter of 2024 for both drugs [1][2]. - A press release on June 27, 2024, indicated that Zenrelia would likely include a boxed warning on safety, which could slow product adoption and reduce the safe administration days for vaccinated dogs by approximately 25% [2]. - Following the announcement, Elanco's share price fell by $3.69, or about 20.53%, from $17.97 to $14.28 per share [2]. Group 3: Allegations in the Lawsuit - The lawsuit alleges that Elanco made false or misleading statements regarding the safety of Zenrelia and the likelihood of meeting its previously issued timelines for the approval and launch of both Zenrelia and Credelio Quattro [3].

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Elanco Animal Health Incorporated due to allegations of misleading statements regarding the safety and approval timelines of its products, Zenrelia and Credelio Quattro [2][3]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses exceeding $100,000 in Elanco between November 7, 2023, and June 26, 2024, to discuss their legal rights [1]. - There is a deadline of December 6, 2024, for investors to seek the role of lead plaintiff in a federal securities class action against Elanco [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [5]. Group 2: Allegations Against Elanco - The complaint alleges that Elanco and its executives violated federal securities laws by making false statements and failing to disclose critical safety information about Zenrelia [3]. - It is claimed that Elanco overstated its business and financial prospects, particularly regarding the approval timelines for Zenrelia and Credelio Quattro [3]. - Following a press release on June 27, 2024, which revealed safety concerns and delayed approval timelines, Elanco's stock price fell by $3.70 per share, or 20.59%, closing at $14.27 per share [4]. Group 3: Product Updates and Market Impact - Elanco's press release indicated that Zenrelia would likely include a boxed warning on safety, which could slow product adoption and limit treatment days by approximately 25% [4]. - The expected FDA approval for Zenrelia is now anticipated in the third quarter of 2024, with a potential commercial launch in the fourth quarter of 2024, while Credelio Quattro is expected to receive FDA approval in the fourth quarter of 2024 [4].

NEW YORK, Oct. 19, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Oct. 17, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Elanco Animal Health Incorporated (NYSE: ELAN) between November 7, 2023 and June 26, 2024, both dates inclusive (the "Class Period"). A class action has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 6, 2024. So what: If you purchased Elanco Animal Health Incorporated ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Elanco Animal Health Incorporated (ELAN) , which belongs to the Zacks Medical - Outpatient and Home Healthcare industry, could be a great candidate to consider. This company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 27 ...

SAN FRANCISCO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Elanco Animal Health (NYSE: ELAN) is facing a securities class action lawsuit alleging the company misled investors about the safety and regulatory path of its new dermatology drug, Zenrelia. Hagens Berman urges Elanco investors who suffered substantial losses to submit your losses now. Class Period: Nov. 7, 2023 – June 26, 2024 Lead Plaintiff Deadline: Dec. 6, 2024 Visit: www.hbsslaw.com/investor-fraud/elan Contact the Firm Now: ELAN@hbsslaw.com 844-916-0895 ...